U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C17H19F2N3O3.CH4O3S
Molecular Weight 447.454
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOMEFLOXACIN MESYLATE

SMILES

CS(O)(=O)=O.CCN1C=C(C(O)=O)C(=O)C2=C1C(F)=C(N3CCNC(C)C3)C(F)=C2

InChI

InChIKey=QHLKJRAHRXUJLD-UHFFFAOYSA-N
InChI=1S/C17H19F2N3O3.CH4O3S/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22;1-5(2,3)4/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25);1H3,(H,2,3,4)

HIDE SMILES / InChI

Description

Lomefloxacin hydrochloride (marketed under the following brand names in English speaking countries Maxaquin, Okacyn, Uniquin) is a fluoroquinolone antibiotic used to treat bacterial infections. It is used to treat chronic bronchitis, as well as complicated and uncomplicated urinary tract infections. It is also used as a prophylactic or preventative treatment to prevent urinary tract infections in patients undergoing transrectal or transurethral surgical procedures. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter. Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MAXAQUIN
Curative
MAXAQUIN
Curative
OKACYN

Cmax

ValueDoseCo-administeredAnalytePopulation
2.8 μg/mL
400 mg 1 times / day steady-state, oral
LOMEFLOXACIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
25.9 μg × h/mL
400 mg 1 times / day steady-state, oral
LOMEFLOXACIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
7.75 h
400 mg 1 times / day steady-state, oral
LOMEFLOXACIN plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended daily dose of Maxaquin (Lomefloxacin) is: Acute bacterial exacerbation of chronic bronchitis 400 mg qd 10 days 400 mg Uncomplicated cystitis in females caused by E coli 400 mg qd 3 days 400 mg
Route of Administration: Oral
In Vitro Use Guide
DNA synthesis in intact cells of E. cloacae, S. marcescens, and K. pneumoniae after 90 min of exposure was inhibited 90% (IC90) by 1 ug of lomefloxacin per ml. For E. coli, the IC50 and the IC90 of lomefloxacin were of the same order of magnitude, regardless of the growth stage of the culture, with IC90s of 0.12 and 0.37 ug/ml obtained for the early and late logarithmic phases, respectively.